Hong Kong is often the first stop for foreign medical device manufacturers entering Asia. The regulatory system is relatively structured, international certifications carry some weight, and the market infrastructure is mature enough to make the process manageable. But for most manufacturers, Hong Kong is a stepping stone. Indonesia is frequently the next market on the list.
The two countries sit close to each other on the map, but operate under very different regulatory frameworks. What worked in Hong Kong does not automatically translate to Indonesia, and the gap between the two systems is wide enough to catch manufacturers off guard if they go in unprepared.
This article covers both markets in sequence. It starts with how medical device registration Hong Kong, then walks through what actually changes when you bring that same product into Indonesia.
Medical Device Registration Hong Kong: How the System Works
The MDACS Framework and the Role of MDD
Medical device regulation in Hong Kong is handled by the Medical Device Division (MDD), which sits under the Department of Health. The MDD administers the Medical Device Administrative Control System, known as MDACS.
In formal terms, MDACS is still a voluntary scheme. In practice, it functions as a prerequisite for any manufacturer that wants to sell into public hospitals or participate in Hospital Authority procurement.
Manufacturers entering the Hong Kong market now should treat listing under MDACS as a requirement, not an option. The regulatory direction is clearly toward mandatory status, and companies that build their processes around voluntary compliance will need to restructure when that transition happens.
Medical Device Classification in Hong Kong
MDACS uses a risk-based classification system that aligns with international standards. General medical devices are placed into four classes: Class I for the lowest-risk products, through to Class IV for the highest-risk. In vitro diagnostic devices follow a parallel structure running from Class A through to Class D, where Class D covers the most sensitive applications such as HIV diagnostics.
The classification a product receives determines the documentation requirements and the overall complexity of the registration process. Getting the classification right at the start matters because reclassification mid-process adds time and cost.
The Registration Process Step by Step
The first step is accurate device classification. This sets the regulatory pathway for everything that follows, and it is worth getting independent confirmation rather than relying solely on the manufacturer’s own assessment.
The second step is appointing a Local Responsible Person, or LRP. Any manufacturer without a physical office in Hong Kong must designate an LRP before submitting an application. The LRP is the official point of contact with the MDD and takes on formal responsibility for compliance and post-market activities on behalf of the manufacturer.
Once the LRP is in place, the manufacturer compiles the registration dossier. For higher-risk devices, this includes the Summary Technical Documentation (STED) and documented evidence of conformity with the Essential Principles of Safety and Performance. The completed dossier is submitted to the MDD through the LRP.
The MDD reviews the submission and may request additional data or clarification. When the review is complete and the device is approved, it receives a unique listing number and is added to the publicly accessible MDACS database. Post-market surveillance, adverse event reporting, and notification of significant product changes are ongoing obligations from that point forward.
The LRP in Hong Kong: What It Is and Where the Risk Lies?
The LRP requirement is straightforward in principle but worth thinking through carefully before appointing someone to the role.
The LRP holds the listing registration. That means they control the formal relationship with the MDD. If a commercial distributor is appointed as LRP, the manufacturer’s flexibility is tied to that relationship. A distributor acting as LRP can decline to process adverse event reports from other distributors, refuse to update the listing, or simply walk away from it if the commercial relationship breaks down. In that scenario, the manufacturer loses the listing and has to start the registration process from scratch.
The practical solution, and the one that avoids this problem entirely, is to appoint an independent LRP that has no commercial stake in how the product is sold. That way, the regulatory and commercial arrangements remain separate, and the manufacturer retains control over both.
ElendiLabs provides a more detailed explanation regarding medical device registration in Hong Kong.
Why Indonesia Is the Natural Next Market for Medical Devices?
Market Scale and Government Commitment
Indonesia is the largest healthcare market in Southeast Asia, with a population of over 270 million and a government that continues to expand its investment in national health infrastructure. But population size alone does not fully explain why manufacturers with a Hong Kong presence are increasingly looking at Indonesia as a priority.
The more compelling reason is policy. The Indonesian Ministry of Health has committed to eliminating cervical cancer by 2030 through the National Action Plan for Cervical Cancer Elimination 2023 to 2030. The plan integrates DNA HPV screening into primary healthcare infrastructure at the grassroots level through the Primary Healthcare Integration framework. A pilot study in East Java, conducted with the involvement of Roche, Biofarma, and Jhpiego, has already demonstrated facility readiness and produced strategic recommendations for national implementation.
The Ministry has been explicit that achieving this goal requires inclusive partnerships with the private sector and international organisations. The government is not just creating a policy framework. It is actively building a procurement pipeline for the diagnostic technology needed to deliver on it.
This is one example, but it reflects a broader pattern. Indonesia’s healthcare agenda is generating sustained, government-backed demand for properly registered medical devices across multiple categories.
What Registration Means in This Context
The connection between national health programs and market access is direct. Without MoH registration, no product can legally participate in the supply chains that support these programs. A manufacturer whose product is not registered cannot bid for government tenders, cannot supply Hospital Authority equivalents, and cannot benefit from the procurement infrastructure the government is building.
Manufacturers who complete registration and establish the right commercial structure early are positioned to enter an active procurement pipeline. Those who wait are positioned to join a queue.
What Changes When You Move from Hong Kong to Indonesia
This is where most manufacturers encounter surprises. The systems share some structural similarities but differ in ways that have real consequences for timeline, commercial structure, and ongoing compliance.
The Regulator Changes Entirely
Hong Kong registration sits with the MDD under the Department of Health. Indonesian registration involves two separate authorities: the Ministry of Health. There is no mutual recognition between the two systems. A listing in Hong Kong provides no shortcut in Indonesia.
Voluntary Versus Mandatory
MDACS is currently voluntary. MoH registration in Indonesia is fully mandatory and actively enforced. There is no grey area. A product that is not registered with MoH cannot be legally imported, distributed, or sold in Indonesia.
Device Classification Does Not Map Directly
Both markets use risk-based classification systems, but the class structures are different. A device classified as Class II under MDACS does not automatically receive an equivalent classification under Indonesia’s system. Reclassification is common when manufacturers assume equivalence without checking, and it adds time if it is not anticipated at the planning stage.
The Local Representative Requirement Is Stricter in Indonesia
Both markets require a local representative. In Hong Kong it is the LRP. In Indonesia it is the local authorised representative or license holder. The concept is similar on the surface, but the commercial implications are more significant in Indonesia.
Indonesia operates under an exclusive distributorship model for product registration. One SKU can only be registered under one distributor. Once a distributor holds the license for a product, replacing them is not straightforward. Manufacturers who appoint a commercial distributor as their license holder can find themselves in the same position as the LRP problem described above, but with fewer options for resolving it.
The independent license holder model exists precisely to address this. By appointing a non-commercial entity as the license holder, the manufacturer keeps the regulatory registration separate from the distribution arrangement.
They can appoint multiple sub-distributors across regions and channels, replace underperforming partners without disrupting the registration, and retain full control over their commercial strategy.
International Certifications Help, but Do Not Replace Mandatory Requirements
CE marking and FDA clearance are accepted as supporting documentation in both markets. In Indonesia, the Certificate of Free Sale from the country of manufacture is the primary mandatory document. CE or FDA approval can reduce how much additional data MoH requests during review, which speeds things up, but it does not replace any of the documents that are required by default.
Additional Compliance Layers That Do Not Exist in Hong Kong
Indonesia has three significant compliance requirements with no equivalent in the Hong Kong system.
CDAKB, the Indonesian Good Distribution Practice certification, has been mandatory for medical device distributors since July 2024. Without a valid CDAKB certification, a company cannot register new products and cannot participate in government tenders. Existing registered products are not affected, but the path forward is blocked until the certification is in place.
TKDN refers to Indonesia’s local content requirements for government procurement. Products with more than 40% Indonesian local content are given mandatory preference in government hospital purchasing decisions. For manufacturers with novel products that have no domestic equivalent, a 0% TKDN figure is generally acceptable. The rules in remote regions such as Papua are more flexible, but hospitals there face a higher risk of government audits, which can make procurement teams cautious regardless.
Halal certification is not yet a hard requirement for medical devices, but a Halal license is already affecting customs clearance because the classification is now applied based on HS codes. Given that between 80 and 90 percent of Indonesia’s population is Muslim, stricter labelling requirements for non-halal products are expected. Manufacturers who hold halal assessments from recognised bodies in countries such as the United States or United Kingdom can use mutual recognition to speed up the local process, but this does not automatically grant halal status in Indonesia.
Registration Timelines
Hong Kong can move faster for lower-risk device classes. Indonesia is realistically 2.5 to 3 months for a Class A medical device under normal conditions, assuming documents are prepared correctly and the submission process moves without system delays.
Handling Both Markets Through One Partnership
Managing regulatory submissions in two different markets through separate, uncoordinated consultants creates duplication. Documents prepared for one market need to be adapted for the other. Timelines need to be planned together to avoid situations where one market is ready and the other is not. And when questions arise, having two independent advisors who are not talking to each other makes getting a consistent answer harder than it should be.
Product Registration Indonesia has partnered with ElendiLabs to give manufacturers a coordinated path into both markets. ElendiLabs handles medical device registration in Hong Kong, including LRP appointment and post-market compliance. PRI manages the full registration and market entry process in Indonesia, including the independent license holder service.
For manufacturers entering both markets, the two firms work together so that document preparation, timeline planning, and compliance management are coordinated from the beginning rather than treated as two separate projects.
ElendiLabs also operates as a global regulatory consultancy platform that connects manufacturers with verified regulatory experts across multiple markets. For companies planning expansion beyond Hong Kong and Indonesia, the platform offers access to specialist knowledge in markets across Asia Pacific, Europe, and beyond.
Before You Start the Indonesia Process
A few things are worth confirming before beginning:
- Check that your device classification under MDACS corresponds correctly to the Indonesian classification system. Do not assume equivalence.
- Decide early whether your local authorised representative in Indonesia will be a commercial distributor or an independent entity. This decision affects your commercial flexibility for the entire time the product is on the market.
- Make sure your Certificate of Free Sale is current and correctly apostilled or authenticated for Indonesia. This is the document that most often causes delays when it is not prepared in advance.
- If you are targeting government procurement, factor in CDAKB and TKDN from the start, not after registration is complete.
- If you are planning to register a medical device in Indonesia and want to understand what the process looks like for your specific product, our team is available to walk you through it.
Ready to discuss your market entry plan? Schedule a consultation with our team.
